Yahong Pharmaceuticals announced that the company's product APL-1702, used for treating high-grade cervical squamous intraepithelial lesions, had the results of the international multicenter Phase III clinical trial selected for the 2024 International Photodynamic Therapy and Photodiagnosis Conference. The efficacy data on reducing the pathological grading of precancerous cervical lesions were presented in the form of an oral presentation at the conference. The current market application for this product has been accepted by the National Medical Products Administration, but the success of its market launch and timing are uncertain.